drugset / Trial / NCT04900519
Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a first-in-human, phase 1, open-label, dose-escalation study of STI-6643 administered by intravenous infusion in subjects with a relapsed/refractory advanced solid tumor.
Timeline
- Start
- 2021-11-24
- Primary completion
- 2024-12
- Completion
- 2025-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | STI-6643 | Unknown | — | Intravenous |